RESUMEN
INTRODUCTION: Heart failure in patients with non-valvular atrial fibrillation (NVAF) is two to three times more common than in individuals without NVAF. OBJECTIVE: To identify cardiometabolic risk factors (CMRF) and antithrombotic treatment in patients with NVAF and heart failure with reduced ejection fraction (HFrEF), and to determine if there were differences according to gender. METHODS: CMRF, pro-thrombotic risk, bleeding risk, and antithrombotic therapy were globally analyzed and according to gender. RESULTS: Out of 1,423 patients with NVAF, 336 had HFrEF. On average, females were older than males. There was no difference between genders with regard to the type of NVAF or direct oral anticoagulants use. Hypertension was more common in women. History of transient ischemic attack was reported in 3.6% of the patients and cerebrovascular event in 10%, without differences in terms of gender. The percentage of men with elevated embolic risk was higher, but without antithrombotic treatment, in comparison with women. CONCLUSIONS: Significant differences were found according to gender in patients with NVAF and HFrEF, both in CMRF and some comorbidities, as well as in antithrombotic treatment according to embolic and bleeding risk.
INTRODUCCIÓN: La insuficiencia cardiaca en pacientes con fibrilación auricular no valvular (FANV) es de dos a tres veces más frecuente que en individuos sin FANV. OBJETIVO: Identificar los factores de riesgo cardiometabólico (FRCM) y el tratamiento antitrombótico de pacientes con FANV e insuficiencia cardiaca con fracción de expulsión reducida (IC-FEr), y determinar si existen diferencias conforme al sexo. MÉTODOS: En forma global y de acuerdo con el sexo se analizaron FRCM, riesgo protrombótico, riesgo de sangrado y terapia antitrombótica. RESULTADOS: De 1423 pacientes con FANV, 336 tuvieron IC-FEr. Las mujeres promediaron mayor edad que los hombres. No hubo diferencia entre los sexos respecto al tipo de FANV o uso de anticoagulantes orales directos. La hipertensión arterial sistémica fue más frecuente en mujeres. Un 3.6 % de los pacientes reportó antecedente de ataque isquémico transitorio y 10 % de evento vascular cerebral, sin diferencias en cuanto al sexo. El porcentaje de hombres con riesgo embólico elevado fue mayor, pero sin tratamiento antitrombótico, en comparación con las mujeres. CONCLUSIONES: Se encontraron diferencias significativas de acuerdo con el sexo en pacientes con FANV e IC-FEr, tanto en FRCM y algunas comorbilidades, como en el tratamiento antitrombótico de acuerdo con el riesgo embólico y de sangrado.
Asunto(s)
Fibrilación Atrial , Insuficiencia Cardíaca , Accidente Cerebrovascular , Humanos , Masculino , Femenino , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Anticoagulantes/efectos adversos , Fibrinolíticos/efectos adversos , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/epidemiología , Factores de Riesgo Cardiometabólico , Volumen Sistólico , Factores de Riesgo , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/prevención & controlRESUMEN
Reel syndrome is characterized by the rotation of permanent pacemaker generator on its transverse axis and electrode catheters curl around it, so this causes displacement of the electrodes with the loss of atrial and ventricular pacing. It can cause severe symptoms due to dysfunction of the pacemaker. We present three patient cases who after the placement of pacemaker attended by dysfunction of the displacement of the electrodes their clinical pictures were compatible with Reel syndrome.
Asunto(s)
Falla de Equipo , Marcapaso Artificial , Femenino , Humanos , Persona de Mediana Edad , SíndromeRESUMEN
BACKGROUND: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown. OBJECTIVE: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey. METHODS: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure. RESULTS: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe. CONCLUSION: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.
Asunto(s)
Bloqueo Atrioventricular , COVID-19 , Control de Infecciones , Complicaciones Posoperatorias , Implantación de Prótesis , SARS-CoV-2/aislamiento & purificación , Síndrome del Seno Enfermo , Anciano , Bloqueo Atrioventricular/epidemiología , Bloqueo Atrioventricular/terapia , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/terapia , Comorbilidad , Desfibriladores Implantables/estadística & datos numéricos , Femenino , Salud Global/estadística & datos numéricos , Humanos , Control de Infecciones/instrumentación , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Masculino , Persona de Mediana Edad , Mortalidad , Evaluación de Resultado en la Atención de Salud , Marcapaso Artificial/estadística & datos numéricos , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/mortalidad , Implantación de Prótesis/efectos adversos , Implantación de Prótesis/instrumentación , Implantación de Prótesis/mortalidad , Factores de Riesgo , Síndrome del Seno Enfermo/epidemiología , Síndrome del Seno Enfermo/terapia , Encuestas y CuestionariosRESUMEN
Atrial fibrillation is the most common cardiac arrhythmia responsible for a significant morbidity and mortality. In recent years, progress has been made in determining the genetic abnormalities, the use of anticoagulants as a component of a primary treatment strategy in many patients who have a high risk of recurrence and for thromboembolism, and newer and safer antiarrthythmics are now available. The aim of this paper is to discuss about this topic and antiarrhythmic therapy.
Asunto(s)
Antiarrítmicos/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
[Figure: see text].
Asunto(s)
Arritmias Cardíacas/epidemiología , COVID-19/epidemiología , Salud Global/tendencias , Anciano , Arritmias Cardíacas/mortalidad , Arritmias Cardíacas/fisiopatología , Arritmias Cardíacas/terapia , COVID-19/mortalidad , COVID-19/terapia , Electrofisiología Cardíaca/tendencias , Comorbilidad , Técnicas Electrofisiológicas Cardíacas/tendencias , Femenino , Encuestas de Atención de la Salud , Disparidades en Atención de Salud , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina/tendencias , Prevalencia , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de TiempoRESUMEN
Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients ≥18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects <65 years to 22.5% in those ≥75 years old (P <0.0001). Concomitantly, an increase in both APD and no antithrombotic treatment was observed with increasing age. DOAC were prescribed equally among all age groups (34.2% in <65, 36.0% in 65-74, and 33.9% in ≥75). According to the type of AF, VKA use was more common in patients with permanent AF (32.7%). A lower use of DOAC was observed in high thromboembolic risk subjects (33.6% in CHA2DS2-VASc ≥2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). Conclusions: VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT02334852. Highlights: CARMEN-AF is a nationwide multi-centric registry seeking to bridge the data gap on anticoagulation therapy for NVAF in Mexico.Elderly patients are more prone to receive suboptimal OAT for NVAF.DOAC were less frequently used in high thromboembolic risk patients (CHA2DS2-VASc ≥2).
Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Fibrinolíticos/uso terapéutico , Sistema de Registros , Accidente Cerebrovascular/prevención & control , Tromboembolia/prevención & control , Factores de Edad , Anciano , Fibrilación Atrial/complicaciones , Femenino , Humanos , Incidencia , Masculino , México/epidemiología , Factores de Riesgo , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología , Tasa de Supervivencia/tendencias , Tromboembolia/complicacionesRESUMEN
Despite the improvement in pharmacologic treatment of heart failure, many patients continue to have severe persistent symptoms, and their prognosis remains poor. One of the most recent advances in heart failure management is the concept of cardiac resynchronization therapy (CRT). Large clinical trials have demonstrated morbidity and mortality benefits of CRT in patients with moderate to severe drug refractory heart failure (New York Heart Association [NYHA] functional class III or IV), and ejection fraction < or = 35% with QRS duration > or = 120 ms.
Asunto(s)
Estimulación Cardíaca Artificial , Insuficiencia Cardíaca/terapia , Humanos , Resultado del TratamientoRESUMEN
In the era of communication technology, new options are available to monitor patients with Automatic Implantable Cardiovascular Devices (AICD) implanted pacemaker (PM) and Automatic Implantable Defibrillators (AID) and Cardiac resynchronization system (CRS). Most companies offer devices with wireless capabilities to communicate automatically with transmitters, allowing remote monitoring device. These systems are being widely used in USA for remote monitoring and have been introduced more recently in Europe, where adoption is increasing. There have also been introduced some systems in Latin America; Mexico in particular has this type of monitoring. This article describes the systems currently existing, available data in the literature in relation to its monitoring and surveillance of the automatic implantable cardiovascular devices (DAIC) and finally, discuss some unresolved issues.
Asunto(s)
Desfibriladores Implantables , Monitoreo Ambulatorio , Marcapaso Artificial , Diseño de Equipo , HumanosRESUMEN
BACKGROUND: Atrial Fibrillation (AF) is associated with an increased risk of stroke and systemic embolism. Several studies have suggested that female AF patients could have a greater risk for stroke. There is scarce information about clinical characteristics and use of antithrombotic therapies in Latin American patients with nonvalvular AF. OBJECTIVE: To describe the gender differences in clinical characteristics, thromboembolic risk, and antithrombotic therapy of patients with nonvalvular AF recruited in Mexico, an upper middle-income country, into the prospective national CARMEN-AF Registry. METHODS: A total of 1423 consecutive patients, with at least one thromboembolic risk factor were enrolled in CARMEN-AF Registry during a three-year period (2014-2017). They were categorized according to Gender. RESULTS: Overall, 48.6% were women, mean age 70⯱â¯12â¯years. Diabetes, smoking, alcoholism, non-ischemic cardiomyopathy, coronary artery disease, and obstructive sleep apnea were higher in men. Most women were found with paroxysmal AF (40.6%), and most men with permanent AF (44.0%). No gender differences were found in the use of vitamin K antagonists (VKA) (30.5% in women vs. 28.0% in men). No gender differences were found in the use of direct oral anticoagulants (DOAC) (33.8% women vs 35.4% men). CONCLUSIONS: CARMEN-AF Registry demonstrates that in Mexico, regardless of gender, a large proportion of patients remain undertreated. No gender differences were found in the use of VKA or DOAC.
RESUMEN
Resumen Introducción: La insuficiencia cardiaca en pacientes con fibrilación auricular no valvular (FANV) es de dos a tres veces más frecuente que en individuos sin FANV. Objetivo: Identificar los factores de riesgo cardiometabólico (FRCM) y el tratamiento antitrombótico de pacientes con FANV e insuficiencia cardiaca con fracción de expulsión reducida (IC-FEr), y determinar si existen diferencias conforme al sexo. Métodos: En forma global y de acuerdo con el sexo se analizaron FRCM, riesgo protrombótico, riesgo de sangrado y terapia antitrombótica. Resultados: De 1423 pacientes con FANV, 336 tuvieron IC-FEr. Las mujeres promediaron mayor edad que los hombres. No hubo diferencia entre los sexos respecto al tipo de FANV o uso de anticoagulantes orales directos. La hipertensión arterial sistémica fue más frecuente en mujeres. Un 3.6 % de los pacientes reportó antecedente de ataque isquémico transitorio y 10 % de evento vascular cerebral, sin diferencias en cuanto al sexo. El porcentaje de hombres con riesgo embólico elevado fue mayor, pero sin tratamiento antitrombótico, en comparación con las mujeres. Conclusiones: Se encontraron diferencias significativas de acuerdo con el sexo en pacientes con FANV e IC-FEr, tanto en FRCM y algunas comorbilidades, como en el tratamiento antitrombótico de acuerdo con el riesgo embólico y de sangrado.
Abstract Introduction: Heart failure in patients with non-valvular atrial fibrillation (NVAF) is two to three times more common than in individuals without NVAF. Objective: To identify cardiometabolic risk factors (CMRF) and antithrombotic treatment in patients with NVAF and heart failure with reduced ejection fraction (HFrEF), and to determine if there were differences according to gender. Methods: CMRF, pro-thrombotic risk, bleeding risk, and antithrombotic therapy were globally analyzed and according to gender. Results: Out of 1,423 patients with NVAF, 336 had HFrEF. On average, females were older than males. There was no difference between genders with regard to the type of NVAF or direct oral anticoagulants use. Hypertension was more common in women. History of transient ischemic attack was reported in 3.6% of the patients and cerebrovascular event in 10%, without differences in terms of gender. The percentage of men with elevated embolic risk was higher, but without antithrombotic treatment, in comparison with women. Conclusions: Significant differences were found according to gender in patients with NVAF and HFrEF, both in CMRF and some comorbidities, as well as in antithrombotic treatment according to embolic and bleeding risk.
RESUMEN
BACKGROUND: Female gender increases the risk of torsades de pointes (TdP) in the long QT syndrome, and this increased risk is assumed to be due to their longer QT interval. OBJECTIVE: The purpose of this study was to study the interplay between gender, duration of the QT interval, and risk of TdP during AV block. METHODS: We studied 250 patients (48% women) with AV block. QT interval was measured at the time of most severe bradycardia. We then constructed different receiver operating characteristic curves for the QTc of males and females for predicting TdP. RESULTS: As expected, patients with TdP had longer QTc intervals than did patients with uncomplicated AV block (564 ± 81 ms vs 422 ± 62 ms, P < .001). This correlation between longer QTc and higher risk of TdP was true for both genders. However, the QT of females with TdP was shorter than the respective value for males with TdP. Despite similar severity of bradycardia, the QT was shorter for females (QT 672 ± 88 ms vs 727 ± 57 ms for females with TdP vs males with TdP, P = .022). The QTc/TdP risk curve for females was shifted to the left in comparison to the pertinent graph for males. Female gender was an independent predictor of TdP. CONCLUSION: Women are at increased risk for developing TdP during AV block, but this increased risk is independent of their longer QT interval. Females develop TdP with QT intervals that are not necessarily arrhythmogenic for males.
Asunto(s)
Bloqueo Atrioventricular/epidemiología , Causas de Muerte , Electrocardiografía , Sistema de Conducción Cardíaco/fisiopatología , Síndrome de QT Prolongado/epidemiología , Torsades de Pointes/epidemiología , Análisis de Varianza , Bloqueo Atrioventricular/diagnóstico , Estudios de Casos y Controles , Intervalos de Confianza , Femenino , Identidad de Género , Humanos , Síndrome de QT Prolongado/diagnóstico , Masculino , Oportunidad Relativa , Prevalencia , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Factores Sexuales , Tasa de Supervivencia , Torsades de Pointes/diagnósticoRESUMEN
Despite the major advances in medical drug therapy, heart failure remains a syndrome with high mortality and morbidity. Biventricular pacing is being tested in congestive heart failure patients with left bundle branch block of an advanced degree. The aim is to resynchronize the dyscoordinate left ventricle contraction. A number of studies are underway, but it is clear that while some patients respond remarkably, this method in highly variable. Accurate identification of patients likely to benefit will be crucial.
Asunto(s)
Estimulación Cardíaca Artificial , Insuficiencia Cardíaca/cirugía , Estimulación Cardíaca Artificial/métodos , Insuficiencia Cardíaca/fisiopatología , Humanos , Marcapaso ArtificialRESUMEN
Atrioventricular nodal reentrant tachycardia is the most frequent regular supraventricular tachycardia. It is generally a benign arrhythmia and usually it is no associated with heart disease. It is more often seen in middle-aged women but it is no infrequent in younger and older patients. The development of radiofrequency with catheter ablation has provided the possibility to definitely cure the arrhythmia and moreover permit a better comprehension of the underlying electrophysiologic and anatomic substrate.
Asunto(s)
Ablación por Catéter/métodos , Taquicardia por Reentrada en el Nodo Atrioventricular/cirugía , Electrocardiografía , Técnicas Electrofisiológicas Cardíacas , HumanosRESUMEN
The Brugada syndrome is an arrhythmic syndrome characterized by a right bundle branch block pattern and an segment elevation in the right precordial leads of the electrocardiogram, in conjunction with a high incidence of sudden death secondary to ventricular tachyarrhythmias. No evidence of structural heart disease is noted during diagnostic evaluation of these patients. The prognosis is poor with up to a 10 per year mortality. Antiarrhythmic drugs have no benefit in prolonging survival. The treatment of choice is the insertion of an implantable cardioverter defibrillator.
Asunto(s)
Electrocardiografía , Bloqueo Cardíaco/fisiopatología , Síncope/fisiopatología , Muerte Súbita , Bloqueo Cardíaco/diagnóstico , Bloqueo Cardíaco/epidemiología , Bloqueo Cardíaco/genética , Bloqueo Cardíaco/terapia , Humanos , Pronóstico , Síncope/diagnóstico , Síncope/epidemiología , Síncope/genética , Síncope/terapia , SíndromeRESUMEN
We present the case of a woman with familial antecedents of a brother who died suddenly at the age of 39 years, and an other with Brugada syndrome. The ECG had not shown the typical pattern of the Brugada syndrome. Based on these antecedents, we decided to perform a pharmacological test with endovenous propafenone, which revealed the electrocardiographic alterations at 10 min after the administration. This is the first case in our knowledge in which endovenous propafenone manifested a concealed Brugada syndrome.
Asunto(s)
Cardiopatías/diagnóstico , Propafenona , Adulto , Arritmias Cardíacas/etiología , Muerte Súbita Cardíaca/etiología , Electrocardiografía , Femenino , Cardiopatías/complicaciones , Cardiopatías/fisiopatología , Humanos , Inyecciones Intravenosas , Propafenona/administración & dosificación , SíndromeRESUMEN
We present the case of a 66 years old man with recurrent episodes of syncope, up to three times during the last two months without previous symptoms. An ECG after the syncope showed a bilateral block (left anterior fascicle block and right bundle branch block) and first grade atrioventricular block. The exercise test did not demonstrate either AV conduction disorders or tachyarrhythmia episodes. Holter monitoring showed premature ventricular complexes; tilt testing and carotid sinus massage were normal. The electrophysiologic study revealed no alteration in the conduction system. Throughout atrial and ventricular stimulation documented no tachyarrhythmias. However, intravenous administration of 12 mg of adenosine induced complete AV infra-His block with ventricular asystolia of 7.2 sec duration. Adenosine testing can identify patients with syncope due to paroxysmal AV block even when the electrophysiological findings and other conventional tests are not conclusive.
Asunto(s)
Adenosina , Bloqueo Cardíaco/complicaciones , Bloqueo Cardíaco/diagnóstico , Síncope/etiología , Anciano , Progresión de la Enfermedad , Electrocardiografía , Bloqueo Cardíaco/fisiopatología , Humanos , MasculinoRESUMEN
38 year old patient with a syncope history and family background of sudden death had an electrocardiogram compatible with the "Brugada Syndrome". When an exercise stress testing with Bruce protocol was done, we found that during the effort phase and at maximum effort, contrary to a ST segment normalization, a discreet increase of the ST segment elevation of 2 mm in V1 and V2 occurred. During recovery phase a decrease in the ST segment elevation was observed, at a normal level as before the test.
Asunto(s)
Bloqueo de Rama/fisiopatología , Electrocardiografía , Prueba de Esfuerzo , Adulto , Muerte Súbita Cardíaca , Humanos , Masculino , Síndrome , Taquicardia Ventricular/fisiopatologíaRESUMEN
Several studies have shown the role of focal trigers in the pulmonary veins initiating episodes of atrial fibrillation. Radiofrequency catheter ablation of this foci is a curative therapy for paroxysmal atrial fibrillation. We report a case of idiopathic paroxysmal atrial fibrillation triggered by abnormal electrical activity in a single pulmonary vein. Mapping was performed during sinus rhythm with a 4F decapolar catheter (Spiral Supreme, Daig, St. Jude Medical) positioned near the ostium by a transseptal approach. Pulmonary vein potentials were only identified in the left superior pulmonary vein. Segmental ostial ablation (30 W) performed during left atrial pacing resulted in complete cesation of conduction in the pulmonary vein. There were no complications. The clinical response (suppression of the paroxysms of atrial fibrillation in a 9-month follow-up) observed in this patient imply that atrial fibrillation was triggered by this pulmonary vein. This case report illustrates several aspects of catheter-based ablation of pulmonary vein foci for the treatment of paroxysmal atrial fibrillation and demonstrates its efficacy.
Asunto(s)
Fibrilación Atrial/terapia , Ablación por Catéter/métodos , Adulto , Cateterismo Cardíaco , Estimulación Eléctrica/métodos , Electrocardiografía , Técnicas Electrofisiológicas Cardíacas/métodos , Humanos , Masculino , Venas Pulmonares/cirugía , Resultado del TratamientoRESUMEN
UNLABELLED: The automatic implantable defibrillator (AID) is the treatment of choice for primary and secondary prevention of sudden death. At the Instituto Nacional de Cardiología, since October 1996 until January 2002, 25 patients were implanted with 26 AID. There were 23 men (92%) and the mean age of the whole group, was 51.4 years. Twenty-three patients (92%) presented structural heart disease, the most common was ischemic heart disease in 13 patients (52%), with a mean ejection fraction of 37.8%. One patient without structural heart disease had Brugada Syndrome. The most frequent clinical arrhythmia was ventricular tachycardia in 14 patients (56%). The mean follow-up was of 29.3 months during which a total of 30 events of ventricular arrhythmia were treated through AID; six of them were inappropriate due to paroxismal atrial fibrillation; 10 AID patients (34%) have not applied for therapy. Three patients (12%) of the group died due to congestive heart failure refractory to pharmacologic treatment. CONCLUSION: The implant of the AID is a safe and effective measure for primary and secondary prevention of sudden death. World-wide experience evidences, that this kind of device has not modified the mortality rate due to heart failure in these patients, but it has diminished sudden arrhythmic death.
Asunto(s)
Arritmias Cardíacas/terapia , Desfibriladores Implantables , Adulto , Anciano , Arritmias Cardíacas/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The importance of atrial fibrillation has always motivated the search of new treatment alternatives. Internal cardioversion has been proposed as a choice in the treatment of atrial fibrillation, giving rise to the development of atrial defibrillator. We present the case of a 68 years old patient without structural heart disease and with diagnosis of chronic atrial fibrillation of 10 months of evolution. He received treatment with antiarrhythmic drugs and successful electrical external cardioversion, but he relapsed a week later. For this reason, we decided to perform internal cardioversion with an electrocatheter (DAIG) placed in the coronary sinus through the right jugular vein and under light sedation with propofol (2 mg/kg weight). We applied three shocks of 1, 3, and 5 joules, being able to convert to sinus rhythm without complications. The patient continues under treatment with antiarrhythmic agents. Internal cardioversion has shown to be an effective way for the treatment of chronic atrial fibrillation, using a light sedation and low energy level to reestablish the sinus rhythm.